Custom In Vivo Tumor Model Services

Online Inquiry

Name *

Email *

Phone *

Services Interested *

Project Description

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

Custom Induced Tumor Model Services

Induced Tumor Models are essential for mimicking the initiation, progression, and therapeutic response of human malignancies. Unlike standard cell-line grafts, induced models—whether driven by specific oncogenes, chemical carcinogens, or direct patient tissues—provide a highly controllable environment to study tumor biology and evaluate novel therapeutics. Alfa Cytology provides a comprehensive suite of induced modeling services. By integrating CRISPR/Cas9 gene editing, chemical carcinogenesis, and PDX-AI translation platforms, we empower pharmaceutical partners to validate targets and screen drug candidates with unprecedented clinical relevance.

Advanced Modeling Technologies for Precision Oncology

Our suite of induction technologies is engineered to replicate clinical disease progression with industrial-grade precision:

CRISPR/Cas9 & iPSC-Based Genetic Platforms

Integration of gene editing with induced pluripotent stem cells (iPSCs) enables bottom-up modeling of oncogenic driver mutations (e.g., KRAS, TP53, RB1) in relevant cellular contexts. This platform supports isogenic comparison and early-stage target validation from the earliest phases of tumorigenesis.

Standardized Chemical Carcinogenesis

Utilizing potent carcinogens like Diethylnitrosamine (DEN) to establish orthotopic hepatocellular carcinoma (HCC) in rats. These models reach a 48%-50% tumor necrosis rate within 8-11 weeks, making them ideal for interventional studies like TACE.

Patient-Derived (PDX/PDTX) Induction

Direct transplantation of patient tumor tissues to preserve the original 3D architecture and genetic heterogeneity. Our PDX platforms support Biomarker Discovery and personalized "co-clinical" trial designs (1-patient-1-model).

Synergistic "In Vitro-to-In Vivo" Pipeline

A dual-track workflow utilizing PDX-derived organoids (PDXO) for high-throughput drug pre-screening, followed by validation in paired in vivo metastatic models to confirm systemic PK/PD and efficacy.

Fig 1. Effect of STAT3 inhibitors on BBN-induced rat tumor-derived BCa organoids. (Singh SP, et al., 2025)

Our Services

Validated Induced Model: Comprehensive Catalog by Carcinogenesis Mechanism

To support the diverse needs of global oncology researchers, Alfa Cytology has established an extensive repository of characterized induced models. By categorizing our models based on their unique induction mechanisms—ranging from genetic engineering to chemical carcinogenesis—we enable you to select the most clinically relevant system for your specific therapeutic target.

Explore our comprehensive library of validated induced models below:

Category	Model Name	Inducing Agent	Target Organ / Pathology
Gastrointestinal	AOM/DSS Model	Azoxymethane + Dextran Sulfate Sodium	Colorectal Cancer (Inflammation-driven)
	MNU-Induced Gastric Model	N-Methyl-N-Nitrosourea	Gastric Adenocarcinoma
	DMH-Induced Colon Model	1,2-Dimethylhydrazine	Colorectal Carcinoma
Hepatic	DEN-Induced HCC Model	Diethylnitrosamine	Hepatocellular Carcinoma (HCC)
	TAA-Induced Liver Model	Thioacetamide	Cholangiocarcinoma / Cirrhotic HCC
	Carbon Tetrachloride Model	CCl₄	Fibrosis-associated Liver Cancer
Pulmonary	Urethane-Induced Model	Ethyl Carbamate (Urethane)	Lung Adenoma / Adenocarcinoma
Pulmonary	NNK-Induced Lung Model	Nitrosamine Ketone	Tobacco-specific Lung Carcinogenesis
Dermatological	Two-Stage Skin Model	7,12-DMBA + TPA	Skin Papilloma / Squamous Cell Carcinoma
Dermatological	UVB-Induced Melanoma	Ultraviolet B Radiation	Cutaneous Melanoma
Urological	BBN-Induced Bladder Model	N-Butyl-N-(4-hydroxybutyl)nitrosamine	Urothelial Carcinoma (Bladder Cancer)
Neurological	ENU-Induced Glioma Model	Ethylnitrosourea	Glioma / Schwannoma
Mammary	DMBA-Induced Breast Model	7,12-Dimethylbenz(a)anthracene	Mammary Adenocarcinoma
Mammary	NMU-Induced Breast Model	N-Nitrosomethylurea	Estrogen-responsive Mammary Cancer
Hematological	Radiation-Induced Leukemia	X-ray / Gamma-ray Radiation	Acute Myeloid Leukemia (AML)
Hematological	Pristane-Induced Plasmacytoma	Pristane Oil (2,6,10,14-tetramethylpentadecane)	Myeloma / Plasmacytoma
Biological/Viral	H. pylori-Induced Model	Helicobacter pylori Infection	Gastric Cancer (MALT Lymphoma)
Biological/Viral	HBV-Transgenic Model	Hepatitis B Virus X protein (HBx)	Chronic Hepatitis to HCC

Why Choose Alfa Cytology?

Translational Excellence

Precision Engineering

Comprehensive Coverage

Regulatory-Ready

Contact Us for Tailored Induced Model Solutions

Alfa Cytology is dedicated to providing the most advanced and clinically relevant Induced Tumor Models in the industry. Whether you are investigating novel epigenetic factors or developing complex interventional therapies, our expert team is ready to support your project from initial model design to final data delivery. Contact us today to discuss how our specialized induction platforms can be tailored to meet your research milestones and accelerate your path to the clinic.

Reference

Singh SP, et al. Stat3 Inhibitors TTI-101 and SH5-07 Suppress Bladder Cancer Cell Survival in 3D Tumor Models. Cells. 2024 Aug 31;13(17):1463. doi: 10.3390/cells13171463. Erratum in: Cells. 2025 Feb 18;14(4):299.

For research use only. Not intended for any clinical use.